Jon H. Hoem

Medical device innovation leader

Baar, Zug, Switzerland

About

Medical device innovation leader and serial entrepreneur for Class IIb and III devices in interventional cardiology, cardiac surgery, echocardiography, electrophysiology and AI-based systems for gastroenterology. Inventor and co-inventor of 14 patents and author of several scientific publications. Currently co-founding Resurgent Heart where we develop a new paradigm for managing cardiogenic shock patients after an acute heart attack with focus on improving the myocardial perfusion. I have more than 38 years global management experience from innovative medical device companies including Board positions (public/private), CEO & co-Founder roles and sales&marketing expertise from Europe, Japan, and the United States. Over time, I have gained solid understanding of governance, medical device funding, product launches, R&D processes, regulatory, clinical, and reimbursement processes. In sum, I can bring advanced medical devices to market world-wide with deep understanding of all entrepreneurial processes for Class IIb/III medical devices. Motto: “Quality • Persistence • Continuous Innovation”

Experience

  • Founder at Cardiac Impact GmbH
    May 2014 - Present · 12 yrs 2 mos

    quality • persistence • continuous innovation Cardiac Impact is developing breakthrough medical devices using lean start-up methodologies.

  • Augere Medical AS (Oslo, Norway · Hybrid)
    • CEO / «Daglig leder»
      Feb 2025 - Mar 2026 · 1 yr 2 mos

      After some exciting months as the Executive Chair at Augere Medical, I’m looking forward to continuing working with the innovative Augere team to bring new AI solutions to our customers and patients!

    • Executive Chair
      Feb 2024 - Feb 2025 · 1 yr 1 mo

      Honored, humbled and excited to join Augere Medical as their Executive Chair! Improved detection of polyps by using AI is a breakthrough for augmented polyp detection rates and hopefully reducing the enormous economic and human burden of colorectal cancer. The Augere PolypAID system, now MDR CE-marked as one of the few systems in Europe, is uniquely positioned to take a substantial market share in the European market and beyond. Proud also that the Augere Board and Augere team are doing such a fantastic job in being close to our customers spurring the life-saving collaboration between clinicians and technicians to improve patient care using AI!

  • Non Executive Board Member at Medistim ASA
    Apr 2023 - May 2025 · 2 yrs 2 mos

    Two interesting years as Medistim independent Board member.

  • CEO / Daglig leder at Pacertool AS
    Mar 2022 - Nov 2023 · 1 yr 9 mos

    Precision: Pacing™ for Heart Failure Patients - the first medical device for selecting the right pacing approach (CRT/CSP/ICD/...) for dyssynchronous heart failure (dysHF) patients

  • Board Observer at Nowwell
    Aug 2021 - Sep 2022 · 1 yr 2 mos